Trial
NCT02695641
Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients
Early Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Mayo Clinic
Collaborators
—
Condition
End Stage Renal Disease
Intervention
1.25mg bevacizumab
Why stopped
Unable to enroll patients for the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-24